Neurocrine Biosciences (NBIX) Tops Q4 EPS by 5c

Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of ($0.51), $0.05 better than the analyst estimate of ($0.56).

2017 Financial Guidance

Revenues from milestones under the AbbVie agreement for 2017 are expected to be $30 million. Ongoing operating expenses for 2017 should approximate $230 million to $240 million, exclusive of the $30 million up-front fee for in-licensing opicapone. The 2017 anticipated expenses include an estimated $40 million of share-based compensation expense. The increase in expected expenses is primarily related to anticipated commercialization activities for INGREZZA in tardive dyskinesia.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• AMC Entertainment launches tender offer for $360M in senior notes
• CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk